Nanjing Sinolife United Co., Ltd. Class H (3332) AI Stock Analysis

• Market Cap: HK$664.25M
• Dividend Yield: N/A
• Average Volume (3M): 83.80K
• Price to Earnings (P/E): 21.9
• Beta (1Y): -0.33
• Revenue Growth: -0.92%
• EPS Growth: -71.88%
• Country: HK
• Employees: 468
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.02
• Shares Outstanding: 946,298,340
• 10 Day Avg. Volume: 27,400
• 30 Day Avg. Volume: 83,800
• PEG Ratio: -0.40
• Price to Book (P/B): 1.22
• Price to Sales (P/S): 0.64
• P/FCF Ratio: -72.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: HK$0.50 ▲(21.95% Upside)

The overall stock score is primarily influenced by strong financial performance, particularly in revenue growth and profitability. However, the lack of recent cash flow data and bearish technical indicators weigh on the score. The valuation is moderate, but the absence of a dividend yield is a drawback for income investors.

Nanjing Sinolife United Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Nanjing Sinolife United Company Limited, an investment holding company, engages in the manufacture, processing, and sale of nutritional supplements in the People's Republic of China, Australia, New Zealand, Vietnam, and internationally. The company is also manufactures and sale of cosmetics and skin care products; and trading, retail, and testing of packaged health food products. It sells its products under the Good Health, Zhongsheng, Hejian, and Cobayer series through a network of retail stores. The company also sells its products through distributors, TV shopping, and e-commerce platforms; and chain pharmacies, health goods supermarkets, and tourist souvenir shops. Nanjing Sinolife United Company Limited was incorporated in 1999 and is headquartered in Nanjing, China.

How the Company Makes Money

Nanjing Sinolife United Co., Ltd. generates revenue through the sale of its health-related products, which include nutritional supplements and functional foods. The company's primary revenue streams come from domestic sales in China, as well as international sales through its distribution networks. Sinolife United capitalizes on its research and development capabilities to innovate and create new products that meet consumer demands. Additionally, the company may engage in strategic partnerships with other businesses in the health sector to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Nanjing Sinolife United Co., Ltd. Class H Financial Statement Overview

Summary

The company shows strong revenue growth and improving profitability with a robust balance sheet characterized by low leverage and high equity. However, the lack of recent cash flow data presents a potential risk to liquidity and cash management.

Income Statement

The company has shown a significant improvement in gross profit margin from the previous year, rising from 67.34% to 71.95%. Net profit margin also improved from 9.33% to 4.62%, indicating better operational efficiency. Revenue growth rate from 2023 to 2024 was a substantial 32.53%, showing strong sales performance. However, EBIT and EBITDA margins decreased slightly, signaling some pressure on operating profitability.

Balance Sheet

The company maintains a strong equity base with an equity ratio of 77.96%, reflecting stability. The debt-to-equity ratio is low at 0.09, indicating conservative leverage. Return on equity is modest at 8.77%, suggesting room for improvement in generating shareholder returns. Overall, the balance sheet shows stability with low financial risk.

Cash Flow

The cash flow statement shows a concerning lack of operating cash flow in the latest year, which could impact liquidity. Previously, free cash flow showed growth, but the absence of cash flow data for 2024 raises concerns about cash management. Free cash flow to net income and operating cash flow to net income ratios are unavailable, limiting the assessment of cash conversion efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	747.90M	563.96M	274.85M	252.32M	296.52M
Gross Profit	538.27M	379.66M	160.00M	138.80M	170.70M
EBITDA	48.19M	75.08M	4.88M	-13.49M	-20.96M
Net Income	34.56M	52.60M	-14.25M	-31.71M	-49.60M
Balance Sheet
Total Assets	505.56M	505.42M	436.99M	390.11M	449.73M
Cash, Cash Equivalents and Short-Term Investments	104.53M	122.79M	78.19M	76.23M	77.12M
Total Debt	33.90M	35.16M	35.75M	8.87M	13.46M
Total Liabilities	111.46M	127.35M	113.19M	59.87M	87.37M
Stockholders Equity	394.10M	378.07M	323.80M	330.24M	362.36M
Cash Flow
Free Cash Flow	-6.65M	44.76M	4.05M	-9.68M	3.20M
Operating Cash Flow	957.00K	47.11M	7.92M	421.00K	16.41M
Investing Cash Flow	-6.00M	449.00K	-3.47M	1.52M	-12.49M
Financing Cash Flow	-4.53M	-4.50M	-4.08M	-4.45M	-34.05M

Nanjing Sinolife United Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.41
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3332, the sentiment is Positive. The current price of 0.41 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.40, and below the 200-day MA of 0.48, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.38 is Neutral, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3332.

Nanjing Sinolife United Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3828	77 Outperform	HK$706.97M	4.98	10.86%	10.10%	6.86%	18.44%
2177	63 Neutral	HK$444.60M	16.69	3.32%	17.24%	-9.26%	435.33%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
2023	62 Neutral	HK$363.93M	6.40	10.92%	―	11.10%	-4.38%
3332	56 Neutral	HK$664.25M	21.93	3.92%	―	-0.92%	-71.88%
2138	46 Neutral	HK$746.68M	19.67	-8.91%	1.54%	-1.68%	-781.88%
0157	41 Neutral	$1.08B	―	-12.38%	―	39.29%	-71.82%

Nanjing Sinolife United Co., Ltd. Class H Corporate Events

Nanjing Sinolife United Reports Decline in First Half 2025 Financial Results

Nanjing Sinolife United Co., Ltd. reported a decrease in revenue by approximately 10.2% to RMB332.4 million for the first half of 2025 compared to the same period in 2024. The company’s gross profit also declined by 9.4%, and profit for the period was significantly lower at RMB15.3 million. The board decided not to declare any interim dividend for this period. These results indicate a challenging period for the company, potentially impacting its market position and stakeholder confidence.

The most recent analyst rating on (HK:3332) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Nanjing Sinolife United Co., Ltd. Class H stock, see the HK:3332 Stock Forecast page.

Nanjing Sinolife United Announces Board Meeting for Interim Results

Nanjing Sinolife United Co., Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend and address other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, as the board will evaluate financial performance and potential dividend distribution, which could impact investor sentiment and market perception.

Nanjing Sinolife Issues Profit Warning Amid Revenue Decline

Nanjing Sinolife United Co., Ltd. has issued a profit warning, indicating a significant decrease in net profit for the first half of 2025 compared to the same period in 2024. The decline is attributed to reduced revenue from distributor channels for infant and child products in Mainland China and increased marketing expenses on e-commerce platforms. The company’s interim results are yet to be finalized, and stakeholders are advised to exercise caution.